Advertisement
Canada markets open in 2 hours
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7262
    -0.0002 (-0.02%)
     
  • CRUDE OIL

    81.91
    -0.82 (-0.99%)
     
  • Bitcoin CAD

    89,340.38
    +2,677.60 (+3.09%)
     
  • CMC Crypto 200

    1,337.78
    +25.16 (+1.96%)
     
  • GOLD FUTURES

    2,389.90
    -8.10 (-0.34%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,460.00
    -87.25 (-0.50%)
     
  • VOLATILITY

    19.40
    +1.40 (+7.78%)
     
  • FTSE

    7,821.81
    -55.24 (-0.70%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6817
    -0.0004 (-0.06%)
     

1 Green Flag and 1 Red Flag For Inovio Pharmaceuticals

1 Green Flag and 1 Red Flag For Inovio Pharmaceuticals

Developing innovative products is an excellent way for a company to become successful, and that's what Inovio Pharmaceuticals (NASDAQ: INO) is looking to do. Let's look at one reason Inovio could be an exciting contrarian buy, and one reason to stay away. Small-cap biotechs need promising pipeline programs to attract attention.